Mereo Biopharma Group Plc ADR (NASDAQ: MREO) on Tuesday, soared 0.44% from the previous trading day, before settling in for the closing price of $2.29. Within the past 52 weeks, MREO’s price has moved between $1.58 and $5.02.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -40.00% annually for the last half of the decade. The company achieved an average annual earnings per share of 40.48%. With a float of $143.85 million, this company’s outstanding shares have now reached $159.00 million.
In an organization with 36 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Mereo Biopharma Group Plc ADR (MREO) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Mereo Biopharma Group Plc ADR is 9.53%, while institutional ownership is 60.80%. The most recent insider transaction that took place on Sep 13 ’24, was worth 253,454. In this transaction Chief Executive Officer of this company sold 60,046 shares at a rate of $4.22, taking the stock ownership to the 808,921 shares. Before that another transaction happened on Sep 12 ’24, when Company’s Chief Executive Officer sold 28,611 for $4.47, making the entire transaction worth $127,968. This insider now owns 868,967 shares in total.
Mereo Biopharma Group Plc ADR (MREO) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 40.48% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.63% during the next five years compared to 34.82% growth over the previous five years of trading.
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Trading Performance Indicators
Mereo Biopharma Group Plc ADR (MREO) is currently performing well based on its current performance indicators. A quick ratio of 8.92 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.31, a number that is poised to hit -0.02 in the next quarter and is forecasted to reach -0.03 in one year’s time.
Technical Analysis of Mereo Biopharma Group Plc ADR (MREO)
Let’s dig in a bit further. During the last 5-days, its volume was 1.01 million. That was inferior than the volume of 1.38 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 35.83%. Additionally, its Average True Range was 0.17.
During the past 100 days, Mereo Biopharma Group Plc ADR’s (MREO) raw stochastic average was set at 31.30%, which indicates a significant increase from 28.57% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.17% in the past 14 days, which was lower than the 68.36% volatility it showed in the past 100 days.
However, in the short run, Mereo Biopharma Group Plc ADR’s stock first resistance to watch stands at $2.35. Second resistance stands at $2.39. The third major resistance level sits at $2.46. If the price goes on to break the first support level at $2.24, it is likely to go to the next support level at $2.17. The third support level lies at $2.13 if the price breaches the second support level.
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Key Stats
Market capitalization of the company is 365.70 million based on 159,000K outstanding shares. Right now, sales total 0 K and income totals -43,250 K. The company made 0 K in profit during its latest quarter, and -12,890 K in sales during its previous quarter.
